| Interactions between Microbiome and DME (MICBIO)
|
| Bacteria: Actinobacteria |
| Streptomyces griseus (actinobacteria) |
Click to Show/Hide the Full List of Drugs: 1 Drugs Metabolized
|
| Doxorubicin |
Click to Show/Hide the Detail |
| Drug ID |
DR0546
Drug Info
|
| Interaction Mechanism |
Human Aldo-keto reductase 1A1 (AKR1A1) and Streptomyces griseus co-metabolize the drug Doxorubicin, which can collectively affect efficacy, safety or bioavailability of this drug. |
[1], [2] |
| Bacteria: Proteobacteria |
| Escherichia coli (enterobacteria) |
Click to Show/Hide the Full List of Drugs: 1 Drugs Metabolized
|
| Doxorubicin |
Click to Show/Hide the Detail |
| Drug ID |
DR0546
Drug Info
|
| Interaction Mechanism |
Human Aldo-keto reductase 1A1 (AKR1A1) and Escherichia coli co-metabolize the drug Doxorubicin, which can collectively affect efficacy, safety or bioavailability of this drug. |
[1], [3] |
| Klebsiella pneumoniae (enterobacteria) |
Click to Show/Hide the Full List of Drugs: 1 Drugs Metabolized
|
| Doxorubicin |
Click to Show/Hide the Detail |
| Drug ID |
DR0546
Drug Info
|
| Interaction Mechanism |
Human Aldo-keto reductase 1A1 (AKR1A1) and Klebsiella pneumoniae co-metabolize the drug Doxorubicin, which can collectively affect efficacy, safety or bioavailability of this drug. |
[1], [3] |
| Neisseria sicca (beta-proteobacteria) |
Click to Show/Hide the Full List of Drugs: 1 Drugs Metabolized
|
| Ethanol |
Click to Show/Hide the Detail |
| Drug ID |
DR0655
Drug Info
|
| Interaction Mechanism |
Human Aldo-keto reductase 1A1 (AKR1A1) and Neisseria sicca co-metabolize the drug Ethanol, which can collectively affect efficacy, safety or bioavailability of this drug. |
[4], [5] |
| Raoultella planticola (enterobacteria) |
Click to Show/Hide the Full List of Drugs: 1 Drugs Metabolized
|
| Doxorubicin |
Click to Show/Hide the Detail |
| Drug ID |
DR0546
Drug Info
|
| Interaction Mechanism |
Human Aldo-keto reductase 1A1 (AKR1A1) and Raoultella planticola co-metabolize the drug Doxorubicin, which can collectively affect efficacy, safety or bioavailability of this drug. |
[1], [3] |
|
|
|
|
|
|